Romosozumab
Romosozumab is an anti-sclerostin antibody used as an anabolic therapy for osteoporosis.
Romosozumab is an anti-sclerostin antibody used as an anabolic therapy for osteoporosis. It is approved for postmenopausal women at high fracture risk and is described as having dual effects on bone formation and bone resorption. Its clinical effects are commonly assessed using bone mineral density (BMD), particularly at the lumbar spine, as well as measures of bone strength and fracture risk.
Current research places romosozumab primarily within postmenopausal osteoporosis treatment, including sequential treatment with denosumab for severe osteoporosis. Other areas include cortical bone remodeling, effects on bone strength around orthopedic hardware, potential use in classical osteogenesis imperfecta, and safety considerations involving cardiovascular disease and medication-related osteonecrosis of the jaw (MRONJ). Studies also examine interactions with factors such as age, body mass index, nutritional status, chronic renal insufficiency, and prior exposure to zoledronate or oral bisphosphonates.
Where the papers sit
10 papers from the last 6 months study romosozumab directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 6 observational · 3 human data · 1 preclinical
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Bone Density Response
Bone-density responses remain broadly consistent across age and BMI, with particularly strong lumbar-spine gains in some underweight patients. The work is moving toward individualized retreatment and cyclic use rather than a single fixed course. Hip responses after readministration may be associated with serum P1NP, especially after bisphosphonate therapy, while TRACP-5b provides a complementary remodeling measure. Whether these biomarkers can guide treatment decisions remains unsettled.
4 papers · 40%
-
Treatment in Severe Osteoporosis
Sequential romosozumab-denosumab treatment is moving toward risk-based selection for severe osteoporosis. Prior medication exposure and clinical predictors are being used to explain differences in fracture and bone-density outcomes. Medication histories are also linked to monitoring for MRONJ, while early reports extend treatment to classical osteogenesis imperfecta. Longer-term safety and the optimal treatment sequence remain open questions.
3 papers · 30%
-
Others — Cardiovascular Safety and Bone Remodeling
Cardiovascular outcomes and prescribing patterns dominate the clinical work, especially in patients with prior cardiovascular disease. Nationwide data examine myocardial infarction and stroke risk relative to other osteoporosis medicines. Separate mouse experiments show rapid trabecular and cortical bone remodeling after treatment. The cluster therefore has no single biological direction beyond balancing cardiovascular safety with skeletal benefit.
3 papers · 30%
Romosozumab need not be confined to a single 12-month treatment course
The study of cyclic romosozumab–denosumab therapy in women at very high fracture risk and the study of romosozumab readministration after bisphosphonate therapy both found that renewed or repeated romosozumab exposure can produce further bone-mineral-density gains 42599329Aug 43033276Nov. This challenges the set's usual picture of romosozumab as a one-time 12-month intervention followed by another agent: treatment can instead be extended or reintroduced in structured cycles, although the second cyclic response was blunted and the readministration finding requires validation.
Romosozumab is being tested as therapy for classical osteogenesis imperfecta rather than acquired osteoporosis
The study of romosozumab in postmenopausal women with classical osteogenesis imperfecta used the anti-sclerostin agent to address a hereditary bone-fragility disorder, finding increased spinal areal bone mineral density after 12 months but less pronounced hip and structural improvement than in severe osteoporosis 42470570Jul. This places romosozumab in a disease category outside the osteoporosis-focused roles represented by the other papers, extending its use to genetically impaired bone quality rather than simply applying the established osteoporosis regimen to another patient subgroup.
Papers
The 10 papers from the last 6 months that study romosozumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Bone Density Response (4)
- Serum P1NP is associated with hip bone mineral density gains after romosozumab readministration following bisphosphonate therapy in women with osteoporosis. Archives of osteoporosis · 14 Nov 2026 PMID 43033276
- Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan. Calcified tissue international · 25 Sept 2026 PMID 42789080
- Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
- Romosozumab Achieves Consistent Lumbar Spine BMD Gains Across All BMI Categories: The Apparent Enhanced Response in Underweight Patients is a Mathematical Artifact of Percentage Change. Calcified tissue international · 27 May 2026 PMID 42203994
Treatment in Severe Osteoporosis (3)
- Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
- Romosozumab in postmenopausal women with classical Osteogenesis imperfecta. Archives of osteoporosis · 18 Jul 2026 PMID 42470570
- Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
Others — Cardiovascular Safety and Bone Remodeling (3)
- Romosozumab Prescribing in Relation to Cardiovascular Disease History in Japan: A Nationwide Claims Database Study. Calcified tissue international · 3 Oct 2026 PMID 42828587
- Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease. Calcified tissue international · 21 Jul 2026 PMID 42479184
- Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749
By study type
Observational studies and case reports (6)
- Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan. Calcified tissue international · 25 Sept 2026 PMID 42789080
- Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
- Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
- Romosozumab in postmenopausal women with classical Osteogenesis imperfecta. Archives of osteoporosis · 18 Jul 2026 PMID 42470570
- Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
- Romosozumab Achieves Consistent Lumbar Spine BMD Gains Across All BMI Categories: The Apparent Enhanced Response in Underweight Patients is a Mathematical Artifact of Percentage Change. Calcified tissue international · 27 May 2026 PMID 42203994
Human data, design not indexed (3)
- Serum P1NP is associated with hip bone mineral density gains after romosozumab readministration following bisphosphonate therapy in women with osteoporosis. Archives of osteoporosis · 14 Nov 2026 PMID 43033276
- Romosozumab Prescribing in Relation to Cardiovascular Disease History in Japan: A Nationwide Claims Database Study. Calcified tissue international · 3 Oct 2026 PMID 42828587
- Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749
Preclinical: animal, cell and lab studies (1)
- Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease. Calcified tissue international · 21 Jul 2026 PMID 42479184
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-02. Drafted by language models from published abstracts; not medical advice.